Reporting of suspected adverse drug reactions after marketing authorisation of a medicinal product is important. It allows continued monitoring of its benefit/risk balance. Healthcare professionals are therefore asked to report any suspected adverse reactions thought either local health agency’s pharmacovigilance department or to the EMA (for residents within an EMA member state), or to Health Canada (for Canadian residents) or to Pharmaceuticals and Medical Devices Agency (for Japanese residents) or by email to BIOCODEX’s pharmacovigilance department to the following address: